GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

Market Cap	389.81B -19.2%
Revenue (ttm)	38.22B +1.9%
Net Income	10.36B +11.7%
EPS	59.73 +9.1%
Shares Out	169.41M
PE Ratio	38.52
Forward PE	33.85
Dividend	45.00 (1.97%)
Ex-Dividend Date	May 29, 2026

Volume	12,265
Open	2,305.00
Previous Close	2,300.10
Day's Range	2,279.00 - 2,312.10
52-Week Range	2,218.00 - 3,515.95
Beta	0.09
Analysts	Buy
Price Target	2,969.75 (+30.07%)
Earnings Date	May 13, 2026

About BOM:500660

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;...

• Industry: Pharmaceutical Preparations
• Founded: 1924
• Employees: 3,113
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500660

Financial Performance

In fiscal year 2026, BOM:500660's revenue was 38.22 billion, an increase of 1.93% compared to the previous year's 37.49 billion. Earnings were 10.36 billion, an increase of 11.69%.